Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1970 1
1974 2
1975 2
1976 1
1977 2
1978 1
1979 1
1981 1
1982 6
1983 3
1984 3
1985 2
1986 3
1987 6
1988 3
1989 6
1990 5
1991 4
1992 12
1993 4
1994 2
1995 3
1996 5
1997 2
1998 1
1999 10
2000 4
2001 10
2002 11
2003 10
2004 7
2005 6
2006 8
2007 13
2008 9
2009 9
2010 10
2011 14
2012 13
2013 23
2014 25
2015 24
2016 17
2017 22
2018 36
2019 39
2020 58
2021 72
2022 111
2023 100
2024 104
2025 101
2026 72

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

909 results

Results by year

Filters applied: . Clear all
Page 1
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.
Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP. Reddel HK, et al. Am J Respir Crit Care Med. 2022 Jan 1;205(1):17-35. doi: 10.1164/rccm.202109-2205PP. Am J Respir Crit Care Med. 2022. PMID: 34658302 Free PMC article.
GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials …
GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because …
Exercise-Induced Asthma: Managing Respiratory Issues in Athletes.
Ora J, De Marco P, Gabriele M, Cazzola M, Rogliani P. Ora J, et al. J Funct Morphol Kinesiol. 2024 Jan 3;9(1):15. doi: 10.3390/jfmk9010015. J Funct Morphol Kinesiol. 2024. PMID: 38249092 Free PMC article. Review.
Inhaled corticosteroids (ICS) are the cornerstone of asthma therapy in athletes. Short-acting beta agonists (SABA) are discouraged as sole treatments. Leukotriene receptor antagonists (LTRA) and mast cell stabilizing agents (MCSA) are potential options. ...
Inhaled corticosteroids (ICS) are the cornerstone of asthma therapy in athletes. Short-acting beta agonists (SABA) are discouraged as …
[OCULAR SYPHILIS].
Zhalka FE, Gepstein R. Zhalka FE, et al. Harefuah. 2022 Oct;161(10):652-658. Harefuah. 2022. PMID: 36315214 Review. Hebrew.
Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme.
Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Nwaru BI, et al. Eur Respir J. 2020 Apr 16;55(4):1901872. doi: 10.1183/13993003.01872-2019. Print 2020 Apr. Eur Respir J. 2020. PMID: 31949111 Free PMC article.
BACKGROUND: Overuse of short-acting beta(2)-agonists (SABA) may indicate poor asthma control and adverse health outcomes. Contemporary population-based data on use, risk factors and impact of SABA (over)use on asthma exacerbations and mortality are scarce, prompting …
BACKGROUND: Overuse of short-acting beta(2)-agonists (SABA) may indicate poor asthma control and adverse health outcomes. Contemporar …
Expert Consensus on SABA Use for Asthma Clinical Decision-Making: A Delphi Approach.
Lugogo N, O'Connor M, George M, Merchant R, Bensch G, Portnoy J, Oppenheimer J, Castro M. Lugogo N, et al. Curr Allergy Asthma Rep. 2023 Nov;23(11):621-634. doi: 10.1007/s11882-023-01111-z. Epub 2023 Nov 22. Curr Allergy Asthma Rep. 2023. PMID: 37991672 Free PMC article. Review.
RECENT FINDINGS: In Phase 1 (n = 100 clinicians), 12% routinely provided patients with 4 SABA prescriptions/year, 73% solicited SABA use frequency at every patient visit, and 21% did not consult asthma guidelines/expert reports. Phase 3 experts (n = 8) reached cons …
RECENT FINDINGS: In Phase 1 (n = 100 clinicians), 12% routinely provided patients with 4 SABA prescriptions/year, 73% solicited S …
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].
Chinese Thoracic Society, Chinese Medical Association. Chinese Thoracic Society, Chinese Medical Association. Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40050074 Chinese.
Non-type 2 inflammation, defined as not meeting any of the above criteria, should be identified only after excluding confounders (e.g., infections and medications) (1, D).Recommendation 7: Patients should undergo psychosocial assessment (e.g., anxiety/depression sca …
Non-type 2 inflammation, defined as not meeting any of the above criteria, should be identified only after excluding confounders (e.g …
Anti-inflammatory reliever therapy (AIR) for asthma.
Levy ML, Crooks MG. Levy ML, et al. ERJ Open Res. 2024 Sep 30;10(5):00494-2024. doi: 10.1183/23120541.00494-2024. eCollection 2024 Sep. ERJ Open Res. 2024. PMID: 39351389 Free PMC article.
SABA overuse is prevalent and dangerous in asthma. Use of anti-inflammatory relievers (ICS/formoterol) in asthma mitigates against risk associated with SABA overuse and poor ICS adherence, and is the preferred approach for asthma management. https://bit.ly/4aHOLn8.. …
SABA overuse is prevalent and dangerous in asthma. Use of anti-inflammatory relievers (ICS/formoterol) in asthma mitigates against ri …
Biological Therapies in Inflammatory Myopathies.
Natour AEH, Kivity S. Natour AEH, et al. Rambam Maimonides Med J. 2023 Apr 30;14(2):e0008. doi: 10.5041/RMMJ.10495. Rambam Maimonides Med J. 2023. PMID: 37116060 Free PMC article. Review.
In the settings of refractory myositis or life-threatening manifestations, e.g. lung involvement or oropharyngeal dysphagia, second-line therapies are needed to minimize disease burden, avoid end-organ damage and steroid toxicity, and decrease mortality. ...This article re …
In the settings of refractory myositis or life-threatening manifestations, e.g. lung involvement or oropharyngeal dysphagia, second-l …
Reply to Paul and Leibovici.
Chowers M, Regev-Yochay G. Chowers M, et al. Clin Infect Dis. 2022 Oct 12;75(8):1485. doi: 10.1093/cid/ciac415. Clin Infect Dis. 2022. PMID: 35818902 Free article. No abstract available.
Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.
Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP. Reddel HK, et al. J Allergy Clin Immunol Pract. 2022 Jan;10(1S):S1-S18. doi: 10.1016/j.jaip.2021.10.001. Epub 2021 Oct 28. J Allergy Clin Immunol Pract. 2022. PMID: 34718211
GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials …
GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because …
909 results